retatrutide study results just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a phase 2 study: • Up to 24.2% mean weight loss at 48 weeks Retatrutide: What It Is &

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus

Macronutrient blends expanded at a 14.1% CAGR through 2030

European journal of pharmacology

When to see a doctor Seek medical evaluation if: Hair loss persists beyond 9 to 12 months after weight stabilization You notice patchy bald spots rather than diffuse thinning Hair loss is accompanied by scalp pain, itching, or redness You have additional symptoms suggesting thyroid or nutritional issues The severity is extreme, with visible scalp showing through Hair loss began before starting tirzepatide or weight loss A dermatologist can perform a pull test, examine the scalp with dermoscopy, and order targeted blood work to distinguish telogen effluvium from other causes

Clinicians should consider obtaining baseline lipid panels before initiating GLP-1 therapy, particularly in patients with known hypertriglyceridemia or other risk factors for pancreatitis

The compound is not approved for therapeutic use anywhere in the world